Document Detail

Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
MedLine Citation:
PMID:  21988216     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Inhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH).
AREAS COVERED: This article first reviews the data supporting the use of infusion prostacyclin and treprostinil as treatments for PAH. The authors then review inhaled treprostinil sodium: the compound and its properties, initial clinical evidence supporting its use and the pivotal data that support a role for inhaled treprostinil sodium in the treatment of patients with PAH. A broad PubMed literature search was done to identify the most current data on the use of treprostinil for PAH. Inhaled treprostinil received FDA approval to improve exercise tolerance in 2009, following the publication of several studies demonstrating its safety and its beneficial effect on hemodynamics, exercise capacity and quality-of-life measures.
EXPERT OPINION: Inhaled treprostinil seems to have a similar efficacy profile as inhaled iloprost, although the demonstrated trough effect on exercise tolerance with treprostinil is an advantage. Perhaps more importantly, the longer half-life makes treprostinil more convenient with four-times-daily dosing. As compared with iloprost, inhaled treprostinil has practical advantages for patients (less frequent dosing, shorter inhalation times, once-daily preparation of the drug delivery device, and easier routine maintenance of the nebulizer), but direct comparisons about efficacy or durability of the treatment effect cannot be made in the absence of carefully controlled trials.
Matthew Ferrantino; R James White
Related Documents :
21805226 - Effects of exercise training associated with continuous positive airway pressure treatm...
9127916 - Low synthesis rate of type i procollagen is normalized during active back rehabilitation.
18657596 - Nociception before and after exercise in rats bred for high and low aerobic capacity.
16915076 - Control of the lumbar neutral zone decreases low back pain and improves self-evaluated ...
2958396 - Metabolism of zearalenone by sow intestinal mucosa in vitro.
8425316 - Cardiorespiratory responses to exercise of patients with aortic stenosis, pulmonary ste...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-12     Completed Date:  2012-02-07     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2583-93     Citation Subset:  IM    
University of Rochester Medical Center, 400 Red Creek Dr, Suite 110, Rochester, NY 14623, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Antihypertensive Agents / administration & dosage,  therapeutic use*
Epoprostenol / administration & dosage,  analogs & derivatives*,  metabolism,  therapeutic use
Exercise Tolerance / drug effects
Hypertension, Pulmonary / drug therapy*,  epidemiology,  metabolism,  physiopathology
Grant Support
Reg. No./Substance:
0/Antihypertensive Agents; 0/treprostinil; 35121-78-9/Epoprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medical management of Crohn's disease.
Next Document:  The extent and nature of need for mealtime support among adults with intellectual disabilities.